Elite Pharmaceuticals (OTCQB: ELTP) schedules Q1 FY 2027 earnings release and investor call
Rhea-AI Filing Summary
Elite Pharmaceuticals, Inc. reported that it will release financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, on August 13, 2026. Management will then host a live conference call on August 14, 2026 at 11:30 AM EDT to discuss financial and operating results and provide a corporate update.
Investors can join the call via domestic dial-in 1-800-346-7359 or international dial-in 1-973-528-0008, using conference number 98840. Stockholders are invited to submit general and financial questions in advance to dianne@elitepharma.com by the deadlines provided in the notice.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Regulation FD regulatory
forward-looking statements regulatory
cGMP technical
DEA-registered regulatory
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
When will Elite Pharmaceuticals (ELTP) release its Q1 FY 2027 financial results?
When is Elite Pharmaceuticals’ (ELTP) conference call for Q1 FY 2027 results?
How can investors join Elite Pharmaceuticals’ (ELTP) August 14, 2026 earnings call?
How can stockholders submit questions for Elite Pharmaceuticals’ (ELTP) earnings call?
What period do Elite Pharmaceuticals’ (ELTP) upcoming results cover?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Item 7.01. Regulation FD Disclosure.
On August 10, 2026, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) issued a press release announcing that the Company will host a conference call to discuss its financial results for the first quarter of fiscal year 2027 ended June 30, 2026, on Thursday, November 14, 2026, at 11:30 AM EDT. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Conference Call Information
| Date: | August 14, 2026 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) |
| 1-973-528-0008 (international) | |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com |
| General questions by 5:00 PM EDT on Wednesday, November 12, 2026 | |
| Financial questions by 7:00 PM EDT on Friday, November 13, 2026 |
The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 10, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: August 10, 2026 | ELITE PHARMACEUTICALS, INC. |
| By: | /s/ Nasrat Hakim | |
| Nasrat Hakim, President and CEO |
Exhibit 99.1
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update
and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026
will be released on Thursday, August 13, 2026
Northvale, NJ – August 10, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite’s management will host a live conference call on Friday, August 14th, at 11:30 AM EDT to discuss the company’s financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.
| Date: | August 14, 2026 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359
(domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EDT on Wednesday, August 12, 2026 Financial questions by 7:00 PM EDT on Thursday, August 13, 2026 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com